Jade Biosciences (JBIO) executive compensation, 2026 proxy

Tom Frohlich, Chief Executive Officer, President and Director, was paid $9.8M in 2025, up 618% from $1.4M the year before.

Filed
April 28, 2026
Annual meeting
June 9, 2026
Pay year
2025
Named executives
4
CEO total pay
$9.8M+618% vs prior year
CEO Base Salary
$621,970Paid in Canadian dollars and converted
CEO Target Bonus
55%Adjusted post-Merger
Bonus Achievement Level
120%Based on corporate performance goals
Pre-Merger Financing
$300MTriggered option replenishment requirements

How Frohlich was paid

$9.8M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary6%Option awards90%Non-equity incentive4%

Named executive officers

ExecutiveTotal
Tom FrohlichChief Executive Officer, President and Director$9,799,759
Andrew King, Ph.D.President, Research and Development$4,541,804
Bradford DahmsChief Financial Officer$4,131,991
Timothy P. NoyesFormer Chief Executive Officer$1,814,483

What changed and why

  • $9.8MTom Frohlich total compensation reached $9,799,759 in fiscal 2025 due to new equity option grants.
  • $630KBase salary for Tom Frohlich increased to $630,000 effective April 2025.
  • 120%Corporate performance goals under the 2025 bonus program achieved 120% payout.
  • $300MPre-Merger Jade completed a $300 million financing triggering replenishment option requirements.
  • $1.6MTimothy P. Noyes received $1,600,716 in severance and benefits upon termination.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.